Brett Monia

“We're pleased to have delivered the real breakthrough for severe hypertriglyceridemia with an incredibly strong, positive, clean label. Unprecedented reductions in acute pancreatitis.”

“I'll be brief, though, because I know you have a lot of questions, Jan, and we want to get to those. But as expected, this has been a highly eventful year for IONIS.”

“The engine, the profile, and the enthusiasm we are seeing in prescribing, we are confident that Tringolza is well-positioned to help a large population of patients in need and become the first Ionis-owned multi-billion-dollar medicine.”

“So we are going through a transition evolution. Really, it's the product of a vision that I laid out when I moved into this role as CEO in January of 2020. Really focused on two key objectives.”

“Let me begin with FCS, though, because that's the current indication for tringolza, patients with a genetic cause of severely elevated triglycerides. The commercial launch for tringolza has been very, very strong, very positive.”